

Molecular Hybridization Strategy in Drug Design: Exploring the Biological Potential of Chalcone Derivatives

Amit Kumar^{1*} 

¹ MET Faculty of Pharmacy, MIT Campus, (Affiliated to Dr. A.P.J. Abdul Kalam Technical University), Ram Ganga Vihar Phase-II, Moradabad, U.P., Pin: 244001

* Correspondence: amkm95461@gmail.com


Received: 28.04.2026; Accepted: 14.06.2026; Published: 14.07.2026

Abstract: Naturally and synthetically derived hybrid molecules are promising sources for new drug development due to their multiple modes of action and their ability to bypass systemic toxicities associated with traditional combination therapies. The rapid escalation of multifactorial diseases such as cancer, neurodegenerative disorders, and multidrug-resistant infections has exposed the limitations of traditional polypharmacy. To overcome these challenges, molecular hybridization has emerged as a cutting-edge paradigm in rational drug design, allowing the scientific community to report dozens of highly potent hybrids. This strategy involves the fusion of two or more distinct pharmacophores into a single multi-target directed ligand. Due to its unique α,β -unsaturated ketone framework, high conformational flexibility, and ease of synthesis, the chalcone scaffold represents a highly privileged template for building a hybrid scaffold as a bioactive agent. This review comprehensively explores the chemical architecture, synthetic methodologies (including green ionic liquid protocols), and profound biological potential of chalcone derivatives. We critically analyze the pharmacodynamic efficacy of various chalcone conjugates, including fluoroquinolone mutual prodrugs for antimicrobial resistance, benzimidazole and α -bromoacryloylamido hybrids for terminal cell cycle arrest in oncology, and sulfonamide chalcones as non-competitive α -glucosidase inhibitors for metabolic syndrome. Finally, we discuss the structure-activity relationship (SAR) profiles and the translational challenges of utilizing chalcone hybrids, highlighting the future integration of nanotechnology and artificial intelligence in overcoming pharmacokinetic barriers.

Keywords: Chalcone derivatives; Molecular hybridization; multi-target directed ligands; Claisen-Schmidt condensation; Drug design; Multifactorial diseases.

Graphical Abstract

Chalcone-Based Molecular Hybridization: Design, Synthesis and Biological Potential for Multi-Target Therapy



© 2025 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The authors retain copyright of their work, and no permission is required from the authors or the publisher to reuse or distribute this article, as long as proper attribution is given to the original source.

1. Introduction

The contemporary pharmaceutical landscape is increasingly challenged by the rapid escalation of multifactorial diseases complex clinical conditions such as metastatic carcinomas, neurodegenerative disorders, metabolic syndromes, and aggressive multi-drug-resistant microbial infections. Historically, the standard pharmacological response to such pathophysiological complexity has been polypharmacy, which involves the co-administration of multiple single-target drugs to simultaneously modulate distinct disease pathways [1-2]. While occasionally effective, polypharmacy frequently results in severe adverse drug-drug interactions, unpredictable pharmacokinetic interference, compounded toxicities, and poor patient compliance [3]. To circumvent these systemic limitations, the strategic paradigm of molecular hybridization has emerged as an unprecedented and highly effective tool in rational drug design. This approach relies on the fusion of two or more distinct pharmacophoric moieties into a single, covalently linked molecular entity, thereby generating a multi-target directed ligand capable of modulating several distinct biological targets concurrently [1].

At the absolute forefront of this hybridization strategy is the chalcone scaffold. Chemically defined as 1,3-diaryl-2-propen-1-ones, chalcones constitute a privileged class of open-chain flavonoids that are widely distributed in the plant kingdom, serving as fundamental precursors in the biosynthesis of flavonoids and isoflavonoids[4]. They are naturally occurring components in various medicinal plants and represent the basic backbone for numerous

polyphenols, alkaloids, tocopherols, and anthocyanins [4]. The structural architecture of a chalcone features two aromatic rings (designated as Ring A and Ring B) interconnected by an α , β -unsaturated carbonyl system, which serves as a highly reactive three-carbon enone bridge[4].

This specific configuration imparts a high degree of conformational flexibility, allowing the molecule to adapt to various enzymatic active sites and receptor binding pockets. More critically, the α , β -unsaturated ketone acts as a powerful Michael acceptor. The molecule possesses a completely delocalized π -electron system that extends across both benzene rings and the central enone bridge[5-7]. Molecules possessing such extended conjugation systems typically exhibit relatively low redox potentials, which facilitates facile electron transfer reactions that are critical for their profound antioxidant and radical scavenging activities [7]. Because the central enone core is structurally permissive, it serves as an ideal template for extensive synthetic modification. By integrating the chalcone backbone with other diverse, biologically active heterocyclic pharmacophores such as coumarins, pyrimidines, benzimidazoles, triazoles, and fluoroquinolones medicinal chemists can design highly selective, potent hybrid agents [4]. The resulting hybridized compounds frequently exhibit pharmacological profiles that are vastly superior to those of their parent molecules, offering broadened spectra of activity, the ability to bypass established multidrug resistance mechanisms, and the potential to significantly mitigate off-target toxicity [1].

2. Chemical Architecture, Stereochemistry, and Conformational Dynamics

To fully appreciate the pharmacological versatility of chalcones, an exhaustive understanding of their stereochemistry and molecular orbital dynamics is required. Chalcones are inherently flexible molecules capable of existing in various conformations, and their biological properties depend heavily on suitable ring substitution patterns and the spatial orientation of the α , β -unsaturated ketone moiety [4].

The stereochemical characteristics of chalcones are defined by two primary structural axes. First, the hydrogen atoms attached to the vinylic double bond ($C_\alpha = C_\beta$) can present in either a *cis* (Z) or *trans* (E) configuration [4]. Thermodynamically, the *trans* (E) isomer is overwhelmingly favored due to the severe steric repulsion that occurs between the bulky aromatic A and B rings when forced into the *cis* geometry [8]. Consequently, the vast majority of naturally occurring and synthetically derived bioactive chalcones exist as the E-isomer. Second, the molecule exhibits conformational isomerism around the single bond connecting the carbonyl carbon to the α -carbon. Free rotation along this sigma bond allows the C = O bond to adopt either an *s-cis* or *s-trans* conformation with respect to the vinylic double bond [4].

The stabilization of these specific conformations is dictated by steric interactions between the substituents on the aromatic rings. Introducing specific electron-donating or electron-withdrawing groups can lock the chalcone into a preferred conformation, resulting in a therapeutically useful agent that optimally aligns with the steric constraints of a target enzyme's active site[4]. Furthermore, the introduction of varied substituents significantly alters the molecular orbital dynamics of the chalcone. Computational analyses utilizing density functional theory reveal that biological efficacy particularly anti-neurotoxic and antioxidant effects closely correlate with the energy gap between the Highest Occupied Molecular Orbital (HOMO) and the Lowest Unoccupied Molecular Orbital (LUMO) [9]. A narrower HOMO-LUMO gap facilitates easier electron excitation and transfer, which is the primary mechanism by which chalcone derivatives quench reactive oxygen species (ROS) and inhibit cellular oxidative stress [9].

3. Comprehensive Synthetic Methodologies and Reaction Kinetics

The ubiquity of chalcones in drug discovery is largely driven by their synthetic accessibility. The fundamental, classical method for generating the chalcone backbone is the Claisen-Schmidt condensation, which is an aldol condensation reaction between a substituted acetophenone and a substituted benzaldehyde [4]. Depending on the specific electronic requirements of the substituents and the desired yield, this reaction can be catalyzed by a remarkably wide array of agents and media, proceeding through either base-catalyzed or acid-catalyzed kinetic pathways.

3.1 Base-Catalyzed E1cB Mechanism

In the traditional base-catalyzed Claisen-Schmidt reaction, strong bases such as sodium hydroxide (NaOH), barium hydroxide ($Ba(OH)_2$), or potassium carbonate (K_2CO_3) are dissolved in polar protic or aprotic solvents like ethanol or dimethylformamide (DMF)[4]. The mechanism initiates with the base abstracting an acidic α -proton from the acetophenone, generating a highly resonance-stabilized enolate anion [8]. Because the aldehyde lacks α -protons (and thus cannot form an enolate), cross-condensation is directed efficiently. The nucleophilic enolate carbon executes an attack on the electrophilic carbonyl carbon of the benzaldehyde, forming a tetrahedral alkoxide intermediate. Following protonation from the solvent, an α,β -hydroxyketone (the aldol adduct) is formed [8].

This intermediate is highly transient. Because it contains an acidic α -proton situated between a carbonyl group and a newly formed hydroxyl group, it undergoes rapid dehydration. In a basic medium, this dehydration proceeds predominantly via an E1cB (Elimination Unimolecular conjugate Base) mechanism [8]. The base removes the α -proton to form a carbanion intermediate, which then expels the hydroxide leaving group, driven by the immense thermodynamic stability gained by forming a fully conjugated α,β -unsaturated system extending from the A-ring to the B-ring [8].

3.2 Acid-Catalyzed E1 Mechanism

Conversely, the acid-catalyzed mechanism operates through the electrophilic activation of the carbonyl species [10-12]. An acid catalyst (such as hydrochloric acid or sulfuric acid) protonates the carbonyl oxygen of the acetophenone, significantly increasing the acidity of its α -hydrogens and promoting rapid tautomerization to the corresponding enol [12]. Simultaneously, the benzaldehyde carbonyl oxygen is protonated, drastically increasing its electrophilicity. The electron-rich double bond of the enol acts as a nucleophile, attacking the activated aldehyde to form a β -hydroxyketone intermediate after deprotonation [12]. Under acidic conditions, the subsequent dehydration step diverges from the basic pathway, occurring instead via an E1 mechanism. The secondary hydroxyl group is protonated to form an excellent leaving group (water), generating a carbocation that rapidly loses an adjacent proton to form the thermodynamically favored trans-alkene (E-isomer) [8].

3.3 Advancements in Green Synthetic Protocols

While conventional condensation is effective, the modern push toward sustainable chemistry has revolutionized chalcone synthesis. Medicinal chemists now routinely utilize eco-friendly, solid-supported, and solvent-free methodologies. Literature documents the successful synthesis of chalcones utilizing clay minerals, ultrasound irradiation, fly-ash: H_2SO_4 reagents, silica-sulphuric acid, dimethylammonium dimethylcarbamate, and potassium fluoride supported on nanoparticles (KF/NP) [4].

A particularly notable advancement is the implementation of task-specific ionic liquids (ILs) as dual-role solvents and catalysts [13-14]. For example, SO_3H -functionalized ionic

liquids such as triethylammonium butylsulfonic acid hydrogen sulfate () have demonstrated remarkable catalytic efficiency. Reactions conducted vigorously at 120 °C under a nitrogen atmosphere utilizing achieved chalcone yields of up to 94% [14]. Beyond high yields, the primary merit of ionic liquids lies in the workup procedure. The resulting chalcone product is inherently immiscible with the ionic liquid phase, allowing for simple physical decantation rather than requiring massive volumes of volatile organic extraction solvents. Furthermore, the ionic liquid can be recycled and reused following heat treatment under a vacuum, perfectly aligning with green chemistry principles [14].

Standard isolation techniques for conventional liquid-phase syntheses remain straightforward. Upon reaction completion, the mixture is typically poured into ice-cold water. Because chalcones are highly lipophilic and insoluble in water, they precipitate as crude solids [12]. If necessary, the mixture is acidified with dilute HCl to neutralize excess base and force precipitation. The solid is collected via vacuum filtration, washed, and purified by recrystallization from hot ethanol to yield analytically pure chalcone derivatives [12].

Table 1. Comparison of Conventional and Green Synthetic Methodologies for Chalcone Synthesis [4].

Synthetic Methodology	Catalyst / Reagent Employed	Key Advantages	Yield & Workup Characteristics
Traditional Base-Catalyzed	NaOH in EtOH; K ₂ CO ₃ in DMF; Ba(OH) ₂	Readily available, inexpensive reagents	Moderate–high yields; requires acid neutralization and extensive washing
Solid-Supported / Green Acid	Silica–sulphuric acid; Fly-ash:H ₂ SO ₄	Minimizes solvent waste; avoids strong liquid acids	High-purity products; catalyst removed by simple filtration
Task-Specific Ionic Liquids	SO ₃ H-functionalized ionic liquids (e.g., triethylammonium butylsulfonic acid hydrogen sulfate)	Functions as both solvent and catalyst; recyclable and environmentally friendly	Up to 94% yield; product separated by decantation; catalyst recoverable and reusable
Mechanochemical / Physical	Ultrasound irradiation; Clay minerals	Rapid reactions with efficient energy transfer; reduced thermal degradation	Excellent yields with simplified work-up and improved selectivity

Table 1 represents comparative overview of conventional and sustainable synthetic methodologies employed for the preparation of chalcone derivatives via the Claisen–Schmidt condensation. The table summarizes representative catalysts or reaction media, major advantages, and typical product isolation characteristics, highlighting the progressive shift from traditional homogeneous base catalysis toward greener approaches such as heterogeneous solid-supported catalysts, task-specific ionic liquids, and mechanochemical activation to improve reaction efficiency, product purity, catalyst recyclability, and environmental sustainability.

4. Pharmacodynamic and Pharmacokinetic Rationale for Hybridization

The decision to construct molecular hybrids using the chalcone scaffold is rooted in specific pharmacodynamic and pharmacokinetic objectives. In multifactorial diseases like cancer and Alzheimer's, single-target inhibition inevitably leads to compensatory pathway

activation. A hybrid molecule physically bridges multiple pharmacophores, generating a single entity that acts as a multi-target directed ligand (MTDL)[1]. For instance, combining a chalcone with a coumarin yields a hybrid capable of simultaneously inhibiting acetylcholinesterase and scavenging free radicals two completely distinct mechanisms essential for treating Alzheimer's disease [6].

From a pharmacokinetic perspective, the synthesis of a hybrid drug ensures that the active components share an identical metabolic profile and reach the target tissue at the exact same concentration and time[1]. This eliminates the complex variable of staggered bioavailability that plagues traditional combination therapies. Furthermore, in the context of infectious diseases, molecular hybridization is an evolutionary countermeasure against cellular resistance[1]. Multidrug-resistant bacteria and cancer cells frequently overexpress efflux pumps (e.g., P-glycoprotein) to extrude therapeutic agents. The substantial molecular weight and unique topological surface area of a hybridized molecule often prevent it from fitting into the binding pockets of these efflux pumps, effectively trapping the drug inside the target cell where it can exert its cytotoxic effects[1].

5. Antimicrobial and Antibacterial Innovations: Bioisosteric Replacements and Mutual Prodrugs

Bacterial resistance to standard antibiotics mandates the continuous discovery of novel antibacterial architectures. Chalcones have long been known to possess intrinsic antibacterial activity, primarily by acting as Michael acceptors that covalently bind to the thiol groups of essential bacterial proteins, disrupting cellular metabolism[15-18]. However, early investigations into the antibacterial potential of natural chalcones, such as Licochalcone A, revealed that specific functional groups, particularly the 4'-hydroxy substituent on the aromatic ring, presented pharmacokinetic liabilities due to rapid metabolic conjugation and poor aqueous solubility[19].

To optimize this, researchers successfully explored bioisosteric replacements. The substitution of the 4'-hydroxy group with a more acidic carboxy group drastically improved aqueous solubility while retaining potent antibacterial efficacy[4]. Further structure-activity mapping demonstrated that incorporating highly lipophilic, electron-withdrawing functional groups, such as dibromo or trifluoromethyl moieties, onto the B-ring of carboxychalcones dramatically enhanced the molecule's ability to penetrate the thick peptidoglycan layers of Gram-positive bacteria[4]. Such optimized hybrids exhibited exceptional potency, with Minimum Inhibitory Concentrations (MIC) as low as 2 μ M to 40 μ M against *Staphylococcus aureus*[4].

Additional synthetic derivations have focused on the integration of aminoacetanilide derivatives. By utilizing the Claisen-Schmidt condensation of substituted benzaldehydes with 4-aminoacetanilide in the presence of a base catalyst, researchers have generated a series of N-(4-aminophenyl)cinnamamide derivatives[4]. These synthesized orange-yellow crystalline powders demonstrated significant antimicrobial activity when benchmarked against standard commercial therapeutics[19-21]. The presence of the cinnamamide linkage enhances the molecule's hydrogen-bonding capacity, facilitating tighter binding to bacterial ribosomal subunits.




Figure 1. Structural Representation: N-(4-aminophenyl)cinnamamide core

5.1 Fluoroquinolone-Chalcone Conjugates as Mutual Prodrugs

A vastly more advanced application of hybridization in antimicrobial therapy involves the synthesis of "mutual prodrugs" or codrugs. Fluoroquinolones, such as ofloxacin, ciprofloxacin, and levofloxacin, are incredibly potent broad-spectrum antibiotics that exert their bactericidal effects by inhibiting bacterial DNA gyrase and topoisomerase IV, effectively halting DNA replication[22]. However, their prolonged clinical use is associated with a severe limitation: the rapid onset of bacterial resistance and the generation of severe oxidative stress in host tissues[22]. To combat this, medicinal chemists have successfully synthesized fluoroquinolone-chalcone conjugates, linking these two pharmacophores via covalent ester or amide bonds[23].

Specifically, the esterification of ofloxacin with appropriately substituted chalcones—such as fluorinated chalcone derivatives (FCD) synthesized from p-fluorobenzaldehyde and p-hydroxyacetophenone, or brominated chalcone derivatives (BCD) synthesized from p-bromobenzaldehyde—yields highly potent mutual prodrugs, designated in literature as P1 and P2 conjugates, respectively[22]. The synthesis of these conjugates frequently employs coupling reagents like 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) to ensure high-yield esterification without degrading the sensitive enone bridge[24-26].

Table 2. Representative fluoroquinolone-based mutual prodrugs and hybrid conjugates incorporating chalcone, peptide, and NSAID pharmacophores for enhanced antimicrobial efficacy and multifunctional therapeutic activity.

Prodrug Conjugate	Pharmacophore 1	Pharmacophore 2	Therapeutic Synergism and Mechanism
P1 Conjugate	Ofloxacin (Fluoroquinolone)	FCD (Fluorinated Chalcone)	Synergistic antibacterial activity against <i>E. coli</i> and <i>P. aeruginosa</i> ; chalcone mitigates ofloxacin-induced oxidative stress. [22]
P2 Conjugate	Ofloxacin (Fluoroquinolone)	BCD (Brominated Chalcone)	Improved lipophilicity enhances Gram-positive penetration; bulky hybrid

			reduces bacterial efflux pump recognition. [22]
Ciprofloxacin–TP10	Ciprofloxacin	Transportan 10 (TP10-NH ₂)	Cell-penetrating peptide markedly enhances intracellular accumulation of ciprofloxacin, improving antimicrobial efficacy. [23]
NSAID Mutual Prodrugs	Ofloxacin	Paracetamol / Salicylic Acid	Dual-action conjugates simultaneously treat bacterial infection and localized inflammation in intestinal bowel diseases. [26]

Table 2 represent fluoroquinolone-based hybrid prodrugs illustrating the integration of chalcone, peptide, and NSAID pharmacophores to enhance antibacterial activity, improve intracellular drug delivery, overcome bacterial resistance, and provide complementary anti-inflammatory effects.

The logic behind the fluoroquinolone-chalcone codrug is deeply synergistic. First, the bulky nature of the conjugated molecule physically hinders its recognition and expulsion by bacterial efflux pumps, thereby neutralizing a primary vector for multidrug resistance[17]. Second, once the prodrug is internalized and the ester bond is cleaved by native bacterial esterases, the hybrid releases the active ofloxacin to fatally inhibit DNA replication. Simultaneously, the localized release of the chalcone derivative directly neutralizes the oxidative free radicals generated by the fluoroquinolone's mechanism of action, protecting host tissues from off-target inflammatory damage[22]. This dual-action mechanism significantly lowers the observed MIC compared to unbound ofloxacin and dramatically enhances the culture sensitivity profiles for both Gram-positive and Gram-negative pathogens[22].

6. Anticancer and Apoptotic Modulators: Mastering Cell Cycle Arrest

In the realm of oncology, chalcone derivatives are inherently cytotoxic to rapidly dividing cells due to their ability to act as Michael acceptors. The α,β -unsaturated carbonyl system reacts selectively with nucleophilic sulfhydryl groups found on cysteine residues of hyperactive cellular proteins, such as tubulin, topoisomerases, and various receptor tyrosine kinases[27-28]. To artificially amplify this inherent cytotoxicity, medicinal chemists have engineered highly electrophilic hybrid chalcones.

6.1 Twin Michael Acceptors: α -Bromoacryloylamido Chalcones

One of the most profound examples of electrophilic enhancement is the synthesis of α -bromoacryloylamido chalcones. These molecular hybrids integrate a secondary Michael acceptor an α -bromoacryloyl moiety directly into the existing α,β -unsaturated ketone framework of the chalcone[29-30]. The presence of twin electrophilic centers radically increases the probability and kinetics of covalent target engagement. Extensive screening of these large libraries (series 1a-m and 2a-k) against diverse human cancer cell lines identified specific configurations as exceptionally potent antiproliferative agents[30].

The most promising lead molecules identified were compounds 1k ((E)-3-Phenyl-1-(2,3,4-trimethoxyphenyl)prop-2-en-1-one), 1m, and 2j, which demonstrated the highest growth-inhibitory activity across all five tested cancer cell lines[30]. The mechanism of action is definitive and terminal. Flow cytometric analysis of K562 leukemia cells exposed to compound 1k revealed a massive accumulation of cells in the sub-G0/G1 peak[30]. This

specific cytometric profile is an unequivocal biochemical marker for extensive DNA fragmentation and late-stage apoptosis. The molecular cascade triggering this arrest involves the permeabilization of the mitochondrial outer membrane, which releases pro-apoptotic factors, including cytochrome c, into the cytosol. This subsequently initiates the formation of the apoptosome and aggressively activates the Caspase-3 executioner pathway, leading to programmed cell death without triggering systemic necrosis[30].

6.2 Benzimidazole-Chalcone Hybrids and Tri-Hybrid Systems

Simultaneously, the hybridization of chalcones with benzimidazole rings has yielded exceptional targeted therapies. Benzimidazoles are nitrogen-rich, bicyclic heterocycles well-documented for their ability to bind to the minor groove of DNA and inhibit tubulin polymerization[31-34]. Fusing this ring with a chalcone scaffold results in compounds with astonishing antineoplastic activity. A prominent example is (2E)-1-(1H-benzimidazol-2-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one.⁷




Figure 2. Structural Representation of (2E)-1-(1H-benzimidazol-2-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one.

This specific benzimidazole-chalcone demonstrated extreme potency against PC12 (pheochromocytoma) and HEPG2 (human liver carcinoma) cell lines, returning an IC_{50} value of 0.103 mM[35]. The 3,4,5-trimethoxyphenyl substitution pattern on the chalcone B-ring is consistently associated with potent antimitotic activity across medicinal chemistry, as it closely mimics the structural geometry of colchicine, allowing the hybrid to lodge into the colchicine-binding site of tubulin and completely inhibit microtubule assembly during mitosis[34]. Furthermore, un-substituted benzimidazole chalcones have also been synthesized and evaluated for their anthelmintic activity, exhibiting potent nematicidal action with an LC_{100} of 0.002 $\mu\text{g/ml}$, proving the vast cross-disciplinary utility of this hybrid class[34].

Further optimization of the benzimidazole-chalcone framework has led to the development of highly complex tri-hybrid systems, specifically benzimidazole-oxadiazole-chalcone conjugates[36-37]. These tri-hybrids act as potent, multi-kinase inhibitors targeting the Epidermal Growth Factor Receptor (EGFR) and the BRAFV600E mutated kinase—two critical oncogenic drivers responsible for uncontrolled proliferation in various human carcinomas[38]. The inclusion of the 1,3,4-oxadiazole ring acts as a rigid, bioisosteric linker

that optimally positions both the chalcone and benzimidazole moieties into the ATP-binding pockets of these target kinases.

Extensive *in vitro* testing of these hybrids (designated as series 7a-x) revealed remarkable cell growth inhibition comparable to doxorubicin, with IC_{50} values ranging from 0.95 μ M to 12.50 μ M across multiple cell lines[38]. The most potent derivative, Compound 7k, induced a massive cell cycle arrest, accumulating 61.95% of MCF-7 breast cancer cells in the G0-G1 phase and 34.86% in the S phase[37]. Western blot analyses confirmed that exposure to Compound 7k, along with 7l and 7m, significantly upregulated the expression of pro-apoptotic executioner proteins including Bax, Cytochrome C, and Caspases 3, 8, and 9, while simultaneously downregulating the anti-apoptotic survival protein Bcl-2 [38]. Molecular docking dynamic simulations confirmed that these hybrids received binding scores almost identical to the co-crystallized clinical standard, Erlotinib, within the EGFR and BRAF active sites[38].

Table 3. Anticancer activity of representative chalcone-based hybrid compounds against diverse human cancer cell lines, highlighting inhibitory potency and principal mechanisms of apoptosis and cell cycle arrest.

Cancer Cell Line	Target Hybrid Compound	Assessed Inhibitory Activity	Primary Cytotoxic / Apoptotic Mechanism
K562 (Leukemia)	α -Bromoacryloylamido Chalcone (Compound 1k)	Highly active	Induces sub-G0/G1 cell cycle arrest and activates the mitochondrial apoptotic pathway via Caspase-3. [30]
PC12 (Pheochromocytoma)	Benzimidazol-2-yl trimethoxyphenyl chalcone	$IC_{50} = 0.103$ mM	Binds to the colchicine site on tubulin, disrupting microtubule assembly and inducing cell cycle arrest. [35]
MCF-7 (Breast)	Benzimidazole–Oxadiazole–Chalcone (Compound 7k)	$IC_{50} = 0.95$ μ M	Potent EGFR and BRAFV600E inhibition; upregulates Bax and cytochrome <i>c</i> while downregulating Bcl-2 to promote apoptosis. [37]
A549 (Lung) / OVCAR-3	Benzimidazole–Chalcone (Compound 23a)	$IC_{50} = 9.73$ μ M (A549)	Demonstrates <i>in vitro</i> cytotoxicity comparable to or exceeding cisplatin against selected cancer cell lines. [29]

Table 3 the Represent anticancer chalcone-based hybrid compounds evaluated against human cancer cell lines, summarizing their inhibitory potency (IC_{50} values) and principal mechanisms of action, including cell cycle arrest, kinase inhibition, tubulin destabilization, and mitochondria-mediated apoptosis.

7. Metabolic and Antidiabetic Hybrids: Revolutionizing Glycemic Control

The clinical management of Type 2 Diabetes Mellitus relies heavily on the strict attenuation of postprandial hyperglycemia. A primary pharmacological mechanism to achieve this is the inhibition of α -glucosidase, an intestinal brush-border hydrolysis enzyme responsible for breaking down complex carbohydrates into absorbable monosaccharides[39-40]. While

clinical standards like acarbose, miglitol, and voglibose are effective, they present significantly disparate pharmacokinetic profiles and severe tolerability issues. Acarbose and voglibose are poorly absorbed from the gut and undergo metabolism in the colon, whereas miglitol is absorbed completely and excreted renally[41-42]. Crucially, because acarbose acts as a competitive inhibitor, it forces unabsorbed carbohydrates into the lower colon where they undergo bacterial fermentation, causing severe gastrointestinal distress (flatulence, diarrhea, abdominal discomfort) which severely limits patient compliance[42].

A paradigm-shifting application of molecular hybridization in metabolic disease is the development of sulfonamide chalcones as a fundamentally new class of α -glucosidase inhibitors[43-44]. Initial studies investigating aminated chalcones revealed a strict structure-activity relationship: while non-aminochalcones (compounds 1-12) exhibited negligible inhibitory activity, the introduction of a primary amine (aminochalcones 13-20) profoundly increased binding affinity to α -glucosidase, α -amylase, and β -amylase[44].

The critical breakthrough occurred when this amine was transformed into a sulfonamide group, generating a scaffold of unparalleled potency. Specifically, 4'-(p-toluenesulfonamide)-3,4-dihydroxy chalcone (Compound 20) emerged as a remarkably potent inhibitor. It yielded an extraordinary IC_{50} of 0.4 μ M, vastly outperforming the clinical standard acarbose, which typically requires concentrations of over 60 μ M (frequently cited near 860 μ M in comparable assays) to achieve similar enzymatic suppression[44]. Further optimization via the synthesis of benzenesulfonyl-aniline chalcone derivatives demonstrated that positioning electron-donating groups on the benzenesulfonyl moiety and electron-withdrawing groups on the aniline ring maximizes the inhibitory activity against α -glucosidase[41].

The profound therapeutic significance of sulfonamide chalcones lies in their enzyme kinetics. Unlike acarbose, these hybridized molecules exhibit purely non-competitive inhibition[44]. This implies that the sulfonamide chalcone does not compete with the carbohydrate substrate for the active site; rather, it binds to a distinct allosteric pocket on the α -glucosidase enzyme. This binding induces a critical conformational change in the enzyme's three-dimensional structure, rendering the primary active site incapable of processing carbohydrates regardless of how much substrate is present. The clinical advantage of non-competitive inhibition is massive: the efficacy of the drug cannot be overwhelmed by a high-carbohydrate meal, providing stable, predictable glycemic control without triggering the explosive gastrointestinal side effects associated with competitive inhibitors[41].

8. Neuroprotective, Anthelmintic, and Multi-Target Directed Hybrids

The structural promiscuity of chalcones makes them excellent candidates for combating parasitic infections and neurodegenerative decline. Anthelmintic drug design has recently focused on fusing chalcones with pyrimidines to produce highly active diazine-based heterocycles[13]. Pyrimidine-chalcone hybrids, generated via the Claisen-Schmidt condensation of substituted acetophenones with thiophene-2-carbaldehyde followed by a subsequent reaction with urea, exhibit remarkable toxicity to parasitic helminths[13]. The pyrimidine ring interferes with the parasite's nucleic acid synthesis, while the chalcone moiety induces rapid muscular paralysis by disrupting oxidative phosphorylation and calcium homeostasis within the organism. These compounds exhibit excellent *in silico* ADME/Toxicity properties, showing sufficient values for absorption, distribution, and excretion to ensure high bioavailability[45-50].

Furthermore, molecular hybridization is extensively utilized in the development of coumarin-chalcone hybrids targeting neurodegenerative disorders, particularly Alzheimer's

and Parkinson's diseases[6]. Coumarins naturally occur as benzopyrone derivatives and possess inherent monoamine oxidase (MAO) and acetylcholinesterase (AChE) inhibitory activities[6]. When hybridized with a chalcone backbone, the resulting compounds act as supreme multi-target agents. For example, compound ChC4 selectively inhibits the MAO-B isoform at submicromolar concentrations, effectively reducing dopamine breakdown in Parkinson's models, while simultaneously suppressing the aggregation of amyloid-beta plaques[16]. The extended, highly lipophilic structure of the coumarin-chalcone hybrid facilitates efficient penetration of the blood-brain barrier (BBB), delivering the drug directly to the central nervous system.

Additionally, specific di- and tri-acetylbenzyl chalcone derivatives have demonstrated extraordinary anti-neurotoxic properties[9]. These hybridized compounds drastically suppress lipopolysaccharide (LPS)-induced nitric oxide (NO) generation in cultured cortical neurons and microglial cells at low concentrations (ranging from 1 to 10 μ M). By aggressively scavenging 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radicals and suppressing neuroinflammation, these hybrids halt the cascade of oxidative stress that typically culminates in neuronal apoptosis, offering a vital therapeutic avenue for halting the progression of neurodegeneration[9].

9. Deep Structure-Activity Relationship (SAR) Profiling

The vast library of synthesized chalcone hybrids allows for the extraction of highly definitive Structure-Activity Relationship (SAR) rules, which serve as a predictive blueprint for future rational drug design.

Table 4. Key structure–activity relationship (SAR) features governing the biological activity of chalcone derivatives through modulation of molecular reactivity, target binding, and pharmacological pathways.

Structural Modification / Parameter	Pharmacological Effect & Mechanism of Action	Major Target Pathway
α,β -Unsaturated Carbonyl Core	Essential Michael acceptor enabling covalent interaction with nucleophilic cysteine residues of target proteins. [4]	General cytotoxic and antimicrobial activity
Electron-Withdrawing Groups (EWGs)	Halogens (F, Cl, Br) or nitro groups increase enone electrophilicity, improving target affinity and lipophilicity (LogP). [4]	Anticancer (kinase inhibition); antibacterial cell wall penetration
Electron-Donating Groups (EDGs)	Hydroxyl, methoxy, and amino substituents enhance electron donation, hydrogen atom transfer, and ROS scavenging. [7]	Antioxidant, anti-inflammatory, and neuroprotective effects
3,4,5-Trimethoxyphenyl Substitution	Mimics colchicine, promoting strong binding to the tubulin colchicine-binding site. [7]	Antimitotic activity and cell cycle arrest
Narrow HOMO–LUMO Energy Gap	Facilitates electron transfer and enhances free radical quenching efficiency. [9]	Anti-neurotoxicity and DPPH radical scavenging
Bulky Hybrid Moieties (e.g., Sulfonamides)	Steric hindrance favors allosteric rather than active-site binding, producing non-competitive inhibition. [44]	Non-competitive enzyme inhibition (e.g., α -glucosidase)

Table 4 represent the Structure–activity relationship (SAR) of chalcone derivatives illustrating the influence of key structural modifications on molecular reactivity, target interactions, and pharmacological activities, including anticancer, antimicrobial, antioxidant, neuroprotective, and enzyme inhibitory effects.

10. Future Perspectives and Translational Challenges

Despite the overwhelming *in vitro* and *in silico* success of molecular hybridization involving chalcone derivatives, translating these complex molecules into functional clinical therapeutics poses formidable challenges.

The primary barrier is pharmacokinetic stability. By definition, hybrid molecules possess significantly higher molecular weights and larger topological polar surface areas than traditional small-molecule drugs. As the molecular weight approaches or exceeds the 500 Dalton threshold, the compounds frequently violate Lipinski's Rule of Five. This results in poor aqueous solubility, reduced intestinal absorption, rapid hepatic metabolism, and consequently, limited oral bioavailability[3]. While strategies like bioisosteric replacement (e.g., swapping hydroxyls for carboxylic acids) temporarily mitigate solubility issues, achieving a delicate balance between lipophilicity (necessary for crossing lipid bilayers and the blood-brain barrier) and hydrophilicity (necessary for systemic circulation) remains a complex optimization problem[3].

Furthermore, the very mechanism that makes chalcones potent their unselective Michael acceptor reactivity can lead to severe off-target toxicity. Highly electrophilic hybrids may indiscriminately alkylate non-target proteins in the bloodstream or liver, forming irreversible covalent adducts that can trigger severe immune responses, hepatotoxicity, or systemic cellular stress. Therefore, current drug design is intensely focused on calibrating the electrophilicity of the enone core, ensuring it is reactive enough to bind its designated pathological target (e.g., a specific overexpressed cancer kinase) but stable enough to circulate safely without binding to highly abundant serum proteins like albumin.

To overcome these physical limitations, future research vectors are heavily leaning toward the integration of chalcone hybrids with nanotechnology and targeted drug delivery systems. Encapsulating potent, highly lipophilic chalcone hybrids such as the α -bromoacryloylamido derivatives or the ofloxacin mutual prodrugs within liposomes, polymeric nanoparticles, or dendrimers could theoretically resolve all solubility constraints[4]. These nanocarriers can provide localized, controlled release directly at the site of infection or within the highly vascularized, leaky tumor microenvironment, protecting the drug from premature degradation while shielding healthy tissues from off-target toxicity.

Additionally, the application of Artificial Intelligence (AI), machine learning, and molecular dynamics simulations in Computer-Aided Drug Design (CADD) is dramatically accelerating the discovery pipeline[4]. By computationally simulating the interactions between theoretical hybrids and virtual target enzymes, researchers can accurately predict binding affinities, metabolic degradation pathways, and toxicological profiles before a single physical compound is synthesized in the laboratory. This *in silico* prescreening ensures that only the most thermodynamically stable and pharmacokinetically viable chalcone hybrids advance to expensive *in vitro* and *in vivo* testing phases.

11. Conclusion

The strategic implementation of molecular hybridization has fundamentally redefined the utility and scope of the chalcone scaffold in medicinal chemistry. No longer restricted to the limitations of simple natural product derivatives or ineffective single-target monotherapies,

modern chalcone hybrids represent highly engineered, multifunctional molecular machines explicitly designed to intercept the overlapping pathological pathways of complex, multifactorial diseases.

The empirical evidence generated through extensive synthetic and pharmacological evaluation is unequivocally compelling. By capitalizing on the permissive nature of the Claisen-Schmidt condensation and integrating modern green chemistry protocols such as ionic liquid catalysis, researchers have generated vast libraries of diverse hybrid agents. The covalent fusion of fluoroquinolones with chalcones has yielded mutual prodrugs that simultaneously eradicate multidrug-resistant bacterial strains, evade efflux pump extrusion, and quench self-induced oxidative stress. In oncology, the integration of benzimidazoles, oxadiazoles, and secondary Michael acceptors with the chalcone backbone has produced highly targeted apoptotic agents capable of destabilizing tubulin, inhibiting mutated oncogenic kinases like EGFR and BRAF, and forcing aggressive carcinomas into terminal cell cycle arrest via mitochondrial permeabilization. Furthermore, the synthesis of sulfonamide chalcones has introduced a new paradigm of non-competitive, allosteric inhibitors of α -glucosidase that vastly outpace traditional clinical therapeutics, offering a highly stabilized, side-effect-minimized approach to managing metabolic syndromes.

Ultimately, as the pharmaceutical industry gradually shifts away from the inherent limitations and toxicities of polypharmacy, and instead embraces the multi-target directed ligand approach, molecular hybridization stands as the preeminent strategy for rational drug design. With continued optimization of pharmacokinetic parameters, careful calibration of Michael acceptor electrophilicity, and the integration of advanced computational modeling and nanotechnological delivery systems, chalcone-based molecular hybrids possess the distinct and undeniable potential to populate the next generation of safe, precise, and highly efficacious therapeutic agents.

Author Contributions

Amit Kumar: Conceptualization, Methodology, Investigation, Data Curation, Formal Analysis, Visualization, Writing Original Draft, Writing Review & Editing, Validation, Supervision, and Final Approval of the Manuscript.

Institutional Review Board Statement

Not applicable

Informed Consent Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable.

Funding

This research received no external funding.

Acknowledgments

The author sincerely expresses heartfelt gratitude to the management and faculty of MET Faculty of Pharmacy, MIT Campus, Moradabad, affiliated with Dr. A.P.J. Abdul Kalam Technical University, Lucknow, for providing continuous encouragement, academic guidance, and an inspiring research environment during the preparation of this review entitled Molecular Hybridization Strategy in Drug Design: Exploring the Biological Potential of Chalcone Derivatives.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

The following abbreviations are used in this manuscript:

Abbreviation	Full Form
AChE	Acetylcholinesterase
ADME	Absorption, Distribution, Metabolism, and Excretion
AI	Artificial Intelligence
ATP	Adenosine Triphosphate
BCD	Brominated Chalcone Derivative
BBB	Blood–Brain Barrier
Bcl-2	B-cell Lymphoma 2
BRAF	v-Raf Murine Sarcoma Viral Oncogene Homolog B
Bax	Bcl-2-associated X Protein
CADD	Computer-Aided Drug Design
Caspase	Cysteine-dependent Aspartate-directed Protease
DPPH	2,2-Diphenyl-1-picrylhydrazyl
DMF	Dimethylformamide
DNA	Deoxyribonucleic Acid
EDC	1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
EDGs	Electron-Donating Groups
EGFR	Epidermal Growth Factor Receptor
EWG	Electron-Withdrawing Group
FCD	Fluorinated Chalcone Derivative
H ₂ SO ₄	Sulfuric Acid
HCl	Hydrochloric Acid
HOMO	Highest Occupied Molecular Orbital
IC ₅₀	Half-Maximal Inhibitory Concentration
IL	Ionic Liquid
K ₂ CO ₃	Potassium Carbonate
KF/NP	Potassium Fluoride-Supported Nanoparticles
LC ₁₀₀	Lethal Concentration Causing 100% Mortality
LogP	Octanol–Water Partition Coefficient
LPS	Lipopolysaccharide

LUMO	Lowest Unoccupied Molecular Orbital
MAO	Monoamine Oxidase
MAO-B	Monoamine Oxidase B
MIC	Minimum Inhibitory Concentration
MTDL	Multi-Target Directed Ligand
NaOH	Sodium Hydroxide
NSAID	Non-Steroidal Anti-Inflammatory Drug
NO	Nitric Oxide
P-gp	P-glycoprotein
P1/P2	Fluoroquinolone–Chalcone Mutual Prodrug Conjugates
ROS	Reactive Oxygen Species
SAR	Structure–Activity Relationship
SO ₃ H	Sulfonic Acid Functional Group
TP10	Transportan 10 Cell-Penetrating Peptide

References

1. Morais, T.S. Recent Advances in the Development of Hybrid Drugs. *Pharmaceutics* **2024**, *16*, 889. <https://doi.org/10.3390/pharmaceutics16070889>
2. Pinheiro, P.d.S.M.; Franco, L.S.; Montagnoli, T.L.; Fraga, C.A.M. Molecular Hybridization: A Powerful Tool for Multitarget Drug Discovery. *Expert Opin. Drug Discov.* **2024**, *19*, 451–470. <https://doi.org/10.1080/17460441.2024.2322990>. (pubmed.ncbi.nlm.nih.gov)
3. Viegas-Junior, C.; Danuello, A.; da Silva Bolzani, V.; Barreiro, E.J.; Fraga, C.A.M. Molecular Hybridization: A Useful Tool in the Design of New Drug Prototypes. *Curr. Med. Chem.* **2007**, *14*, 1829–1852. <https://doi.org/10.2174/092986707781058805>
4. Zhuang, C.; Zhang, W.; Sheng, C.; Zhang, W.; Xing, C.; Miao, Z. Chalcone: A Privileged Structure in Medicinal Chemistry. *Chem. Rev.* **2017**, *117*, 7762–7810. <https://doi.org/10.1021/acs.chemrev.7b00020>
5. Wang, Z. Claisen–Schmidt Condensation. In *Comprehensive Organic Name Reactions and Reagents*; Wiley: Hoboken, NJ, USA, 2010. <https://doi.org/10.1002/9780470638859.conrr145>
6. Rohman, N.; Ardiansah, B.; Wukirsari, T.; Judeh, Z. Recent Trends in the Synthesis and Bioactivity of Coumarin, Coumarin–Chalcone, and Coumarin–Triazole Molecular Hybrids. *Molecules* **2024**, *29*, 1026. <https://doi.org/10.3390/molecules29051026>.
7. Pathak, D.P.; Bansal, H.; Agarwal, U. Chalcone and Their Heterocyclic Analogue: A Review Article. *J. Chem. Pharm. Res.* **2018**, *10*(4), 160–173.
8. Takada, S.C.S.; Nogueira, F.M.; Silva, W.A. Claisen–Schmidt Condensation: An Interdisciplinary Journey in the Organic Synthesis Laboratory. *ChemRxiv* **2024**, Preprint. <https://doi.org/10.26434/chemrxiv-2024-l7jen>
9. Jung, J.-C.; Lee, Y.; Min, D.; Jung, M.; Oh, S. Practical Synthesis of Chalcone Derivatives and Their Biological Activities. *Molecules* **2017**, *22*, 1872. <https://doi.org/10.3390/molecules22111872>.
10. Dotta, D.; Gastaldi, M.; Fin, A.; Barbero, N.; Barolo, C.; Cardano, F.; Rossi, F.; Brunelli, F.; Viscardi, G.; Tron, G.C.; Quagliotto, P. Chalcone Synthesis by Green Claisen–Schmidt Reaction in Cationic and Nonionic Micellar Media. *J. Org. Chem.* **2025**, *90*, 2915–2926. <https://doi.org/10.1021/acs.joc.4c02616>.
11. Akhtar, J.; Khan, A.A.; Ali, Z.; Haider, R.; Shahar Yar, M. Chalcone Derivatives for Biological Potentials: A Strategy of Molecular Hybridization for Drug Design. In *Health and Pharmaceutical Sciences*; Badruddeen, Ed.; BP International: London, UK, **2022**; pp. 29–52. <https://doi.org/10.9734/bpi/hps/v6/11093D>
12. Wang, Z. Claisen–Schmidt Condensation. In *Comprehensive Organic Name Reactions and Reagents*; Wiley: Hoboken, NJ, USA, **2010**. <https://doi.org/10.1002/9780470638859.conrr145>
13. Sahoo, B.M.; Rajeswari, M.; Panda, J.; Sahoo, B. Green Expedient Synthesis of Pyrimidine Derivatives via Chalcones and Evaluation of Their Anthelmintic Activity. *Indian J. Pharm. Educ. Res.* **2017**, *51*(Suppl. 4), S700–S706. <https://doi.org/10.5530/ijper.51.4s.10>

14. Qian, H.; Liu, D.; Lv, C. Synthesis of Chalcones via Claisen–Schmidt Reaction Catalyzed by Sulfonic Acid-Functional Ionic Liquids. *Ind. Eng. Chem. Res.* **2011**, *50*, 1146–1149. <https://doi.org/10.1021/ie101790k>
15. De Freitas Silva, M.; Dias, K.S.T.; Gontijo, V.S.; Ortiz, C.J.C.; Viegas, C. Chalcones Acting as Inhibitors of Cholinesterases, β -Secretase and β -Amyloid Aggregation and Other Targets for Alzheimer's Disease: A Critical Review. *Curr. Med. Chem.* **2021**, *28*, 2827–2856. <https://doi.org/10.2174/0929867327666201021152112> Coumarin-Chalcone Hybrids as Inhibitors of MAO-B: Biological Activity and In Silico Studies, accessed July 14, 2026, <https://www.mdpi.com/1420-3049/26/9/2430>
16. Rajabi, M.; Hossaini, Z.; Khalilzadeh, M.A.; Ezzatzadeh, E.; Emami, S. BDDE-Inspired Chalcone Derivatives to Fight Bacterial and Fungal Infections. *Molecules* **2022**, *27*, 3509. <https://doi.org/10.3390/molecules27113509>
17. Hasan, S.A.; Elias, A.N.; Farhan, M.S. Synthesis, Characterization and Antimicrobial Evaluation of a Series of Chalcone Derivatives. *Der Pharm. Chem.* **2015**, *7*, 39–42
18. Nowakowska, Z.; Kedzia, B.; Schroeder, G. Synthesis, Physicochemical Properties and Antimicrobial Evaluation of New (E)-Chalcones. *Eur. J. Med. Chem.* **2008**, *43*, 707–713. <https://doi.org/10.1016/j.ejmech.2007.05.006>
19. Kello, M.; Drutovic, D.; Pilatova, M.; Tischlerova, V.; Mojzis, J.; Cizmarikova, R.; Kutschy, P.; Mucaji, P.; Jančinová, V.; Nosál, R.; et al. Comprehensive Insight into Anti-Staphylococcal and Anti-Enterococcal Action of Brominated and Chlorinated Pyrazine-Based Chalcones. *Antibiotics* **2022**, *11*, 1185. <https://doi.org/10.3390/antibiotics11091185>
20. Elavarasan, M.; Thamizh Thendral, M.; Syed Shafi, S. Synthesis, Characterisation and Antimicrobial Activity of Some New Chalcones. *Int. J. Pharm. Sci. Res.* **2018**, *9*, 1969–1973. [https://doi.org/10.13040/IJPSR.0975-8232.9\(5\).1969-73](https://doi.org/10.13040/IJPSR.0975-8232.9(5).1969-73)
21. Sahu, N.K.; Balbhadra, S.S.; Choudhary, J.; Kohli, D.V. Synthesis and Antibacterial Evaluation of New Ofloxacin–Chalcone Derivative Conjugates as Possible Mutual Prodrugs. *J. Chem. Pharm. Res.* **2012**, *4*, 794–801.
22. Galdiero, E.; Lombardi, L.; Falanga, A.; Libralato, G.; Guida, M.; Carotenuto, R.; Galdiero, S. Conjugates of Ciprofloxacin and Levofloxacin with Cell-Penetrating Peptide Exhibit Antifungal Activity and Mammalian Cytotoxicity. *Int. J. Mol. Sci.* **2020**, *21*, 5187. <https://doi.org/10.3390/ijms21155187>
23. Nudelman, A. Mutual Prodrugs—Codrugs. *Curr. Med. Chem.* **2023**, *30*, 4283–4339. <https://doi.org/10.2174/092986733066622109102650>
24. Mahdy, M.A.; El-Hadidy, W.F.; Elachy, S.N.; Makar, S.H. Ofloxacin-Associated Retinopathy in Rabbits: Role of Oxidative Stress. *Toxicology* **2008**, *255*, 58–63. <https://doi.org/10.1016/j.tox.2008.10.003>
25. Sahu, N.K.; Kohli, D.V.; Chaturvedi, S.C. Synthesis and Characterization of Mutual Prodrugs of Ofloxacin (4-Fluoroquinolone) with Non-Steroidal Anti-Inflammatory Drugs. *Indian J. Pharm. Sci.* **2008**, *70*, 82–87. <https://doi.org/10.4103/0250-474X.40338>
26. Sahu, N.K.; Balbhadra, S.S.; Choudhary, J.; Kohli, D.V. Synthesis and antibacterial evaluation of new ofloxacin–chalcone derivative conjugates as possible mutual prodrugs. *J. Chem. Pharm. Res.* **2012**, *4*, 794–801.
27. Zhuang, C.; Zhang, W.; Sheng, C.; Zhang, W.; Xing, C.; Miao, Z. Chalcones: Potential Anticancer Agents. In *Anticancer Agents*; IntechOpen: London, UK, 2020. <https://doi.org/10.5772/intechopen.90131>
28. Hsieh, C.-Y.; Ko, P.-W.; Chang, Y.-J.; Kapoor, M.; Liang, Y.-C.; Chu, H.-L.; Lin, H.-H.; Horng, J.-C.; Hsu, M.-H. Design and Synthesis of Benzimidazole-Chalcone Derivatives as Potential Anticancer Agents. *Molecules* **2019**, *24*, 3259. <https://doi.org/10.3390/molecules24183259>
29. Baraldi, P.G.; Carrion, M.D.; Cruz-López, O.; López Cara, C.; Balzarini, J.; Hamel, E.; Canella, A.; Fabbri, E.; Gambari, R.; et al. Hybrid α -bromoacryloylamido chalcones: Design, synthesis and biological evaluation. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 2022–2028. <https://doi.org/10.1016/j.bmcl.2009.02.0387>
30. Romagnoli, R.; Baraldi, P.G.; Carrion, M.D.; Cara, C.L.; Cruz-López, O.; Preti, D.; Fruttarolo, F.; Pavani, M.G.; Tabrizi, M.A.; Tolomeo, M.; et al. Hybrid α -Bromoacryloylamido Chalcones: Design, Synthesis and Biological Evaluation. *Bioorg. Med. Chem.* **2009**, *17*, 6862–6871. <https://doi.org/10.1016/j.bmc.2009.08.022>

31. Yao, H.; Tao, X.; Xu, L.; Qi, Y.; Yin, L.; Han, X.; Xu, Y.; Zheng, L.; Peng, J. Novel chalcone derivatives as potent Nrf2 activators in mice and human lung epithelial cells. *J. Med. Chem.* **2011**, *54*, 4327–4333. <https://doi.org/10.1021/jm2002348>
32. de Oliveira, T.B.; de Moraes Gomes, P.A.T.; de Oliveira, M.R.; da Silva, C.R.; de Oliveira, K.M.; da Silva, A.D. Phosphonium Salt Displays Cytotoxic Effects Against Human Cancer Cell Lines. *Chem. Biol. Interact.* **2017**, *278*, 212–218. <https://doi.org/10.1016/j.cbi.2017.10.016>
33. Alshamrani, M.Y.; Alghamdi, B.S.; Alzahrani, A.M.; Alqahtani, S.S.; Alshammari, A.; Alanazi, F.K.; Alfaifi, M.Y.; Alharbi, K.S.; Albratty, M.; Makeen, H.A.; et al. Indole Compounds in Oncology: Therapeutic Potential and Mechanistic Insights. *Pharmaceuticals* **2024**, *17*, 922. <https://doi.org/10.3390/ph17070922>
34. Jaiswal, P.; Pathak, D.P.; Bansal, H.; Agarwal, U. Chalcone and Their Heterocyclic Analogue: A Review Article. *J. Chem. Pharm. Res.* **2018**, *10*, 160–173
35. Wang, Y.; Zhang, H.; Wang, J.; Li, Y.; Wang, X.; Zhang, S.; Liu, H. Design, synthesis and biological evaluation of 3',4',5'-trimethoxy flavonoid benzimidazole derivatives as potential anti-tumor agents. *Eur. J. Med. Chem.* **2018**, *143*, 1823–1836. <https://doi.org/10.1016/j.ejmech.2017.10.062>
36. Abbas, S.H.; Gomaa, H.A.M.; Youssif, B.G.M.; Sayed, A.M.; Abdelhamid, D.; Abdel-Aziz, M. Chalcone/1,3,4-Oxadiazole/Benzimidazole hybrids as novel anti-proliferative agents inducing apoptosis and inhibiting EGFR and BRAFV600E. *BMC Chem.* **2023**, *17*, 116. <https://doi.org/10.1186/s13065-023-01003-0>
37. Hagar, F.F.; Abbas, S.H.; Gomaa, H.A.M.; Youssif, B.G.M.; Sayed, A.M.; Abdelhamid, D.; Abdel-Aziz, M. Chalcone/1,3,4-oxadiazole/benzimidazole hybrids as novel anti-proliferative agents inducing apoptosis and inhibiting EGFR & BRAFV600E. *BMC Chem.* **2023**, *17*, 116. <https://doi.org/10.1186/s13065-023-01003-3>
38. Gomaa, H.A.M.; Youssif, B.G.M.; Sayed, A.M.; Abdelhamid, D.; Abdel-Aziz, M. Chalcone/1,3,4-oxadiazole/benzimidazole hybrids as novel anti-proliferative agents inducing apoptosis and inhibiting EGFR & BRAFV600E. *BMC Chem.* **2023**, *17*, 116. <https://doi.org/10.1186/s13065-023-01003-3-2>
39. Irfan, R.; Mousavi, S.; Alazmi, M.; Saleem, R.S.Z. A Comprehensive Review of Aminochalcones. *Molecules* **2020**, *25*, 5381. <https://doi.org/10.3390/molecules25225381>
40. Seo, W.D.; J.H.; Kang, J.E.; Ryu, H.W.; Curtis-Long, M.J.; Lee, H.S.; Yang, M.S.; Park, K.H. Synthesis of sulfonamide derivatives as α -glucosidase inhibitors. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 5514–5516. <https://doi.org/10.1016/j.bmcl.2005.08.087>
41. Hall, H.; Perelman, D. *Alpha-Glucosidase Inhibitors*. In *StatPearls*; StatPearls Publishing: Treasure Island, FL, USA, 2024. Available online: <https://www.ncbi.nlm.nih.gov/books/NBK55784>
42. Osmosis. *Alpha-Glucosidase Inhibitors for Diabetes: Pharmacology Made Easy* [Video]. YouTube. Published July 2020. Available from: <https://www.youtube.com/watch?v=JlJcBehQl20>
43. Seo, W.D.; Kim, J.H.; Kang, J.E.; Ryu, H.W.; Curtis-Long, M.J.; Lee, H.S.; Yang, M.S.; Park, K.H. Sulfonamide chalcone as a new class of α -glucosidase inhibitors. *Bioorganic & Medicinal Chemistry Letters* **2005**, *15*(24), 5514–5516. <https://doi.org/10.1016/j.bmcl.2005.08.087>
44. Abu Bakar, M.H.; Mohamad, N.; Zulkifli, R.M.; Abdullah, N. A Review of the *In Vitro* Inhibition of α -Amylase and α -Glucosidase by Chalcone Derivatives. *Evidence-Based Complementary and Alternative Medicine* **2023**, *2023*, Article ID 6677378. <https://doi.org/10.1155/2023/6677378>
45. Salehi, B.; Quispe, C.; Chamkhi, I.; El Omari, N.; Balahbib, A.; Sharifi-Rad, J.; Bouyahya, A.; Akram, M.; Iqbal, M.; Docea, A.O.; Caruntu, C.; Leyva-Gómez, G.; Dey, A.; Martorell, M.; Calina, D.; López, V.; Les, F. *Pharmacological Properties of Chalcones: A Review of Preclinical Including Molecular Mechanisms and Clinical Evidence*. *Frontiers in Pharmacology* **2021**, *11*, 592654. <https://doi.org/10.3389/fphar.2020.592654>
46. Alblewi, F.F.; Okasha, R.M.; Hritani, Z.M.; Alnoman, R.B.; Aljohani, A.S.; Althobaiti, Y.S.; Alanazi, M.M.; Elkaeed, E.B.; El Kerdawy, A.M. Synthesis, molecular docking, and *in vitro* studies of pyrimidine-2-thione derivatives as antineoplastic agents via potential RAS/PI3K/Akt/JNK inhibition in breast carcinoma cells. *Molecules* **2022**, *27*(24), 8900. <https://doi.org/10.3390/molecules27248900>
47. Neelaveni, K.; Rajendra Prasad, Y.; Krishna, K. Thiophene-bearing pyrimidine derivatives synthesis from chalcones: In silico ADME/T studies and molecular docking studies. *Journal of Pharmaceutical Negative Results* **2022**, *13*(Special Issue 7), 1961–1968. <https://doi.org/10.47750/pnr.2022.13.S07.269>
48. Kang, L.; Gao, X.-H.; Liu, H.-R.; Men, X.; Wu, H.-N.; Cui, P.-W.; Oldfield, E.; Yan, J.-Y. Structure–activity relationship investigation of coumarin–chalcone hybrids with diverse side-chains as

acetylcholinesterase and butyrylcholinesterase inhibitors. *Molecular Diversity* **2018**, 22(4), 893–906. <https://doi.org/10.1007/s11030-018-9839-y>

49. Rajendran, G.; Bhanu, D.; Aruchamy, B.; Ramani, P.; Pandurangan, N.; Bobba, K.N.; Oh, E.J.; Chung, H.Y.; Gangadaran, P.; Ahn, B.-C. *Chalcone: A Promising Bioactive Scaffold in Medicinal Chemistry. Pharmaceuticals* **2022**, 15(10), 1250. <https://doi.org/10.3390/ph15101250>.

Publisher's Note & Disclaimer

The statements, opinions, and data presented in this publication are solely those of the individual author(s) and contributor(s) and do not necessarily reflect the views of the publisher and/or the editor(s). The publisher and/or the editor(s) disclaim any responsibility for the accuracy, completeness, or reliability of the content. Neither the publisher nor the editor(s) assume any legal liability for any errors, omissions, or consequences arising from the use of the information presented in this publication. Furthermore, the publisher and/or the editor(s) disclaim any liability for any injury, damage, or loss to persons or property that may result from the use of any ideas, methods, instructions, or products mentioned in the content. Readers are encouraged to independently verify any information before relying on it, and the publisher assumes no responsibility for any consequences arising from the use of materials contained in this publication.